Loading
Loading
Tissue Repair & Recovery · 5mg
Choose dose
Janoshik-tested · 10 vials per kit
KPV is a natural tripeptide studied in preclinical research for its anti-inflammatory, antimicrobial, and wound-healing properties. Research has examined its potential to regulate immune response, combat pathogens including Staphylococcus aureus and Candida albicans, and accelerate skin cell repair and collagen production. Studies have also explored its role in inflammatory bowel disease management and post-surgical recovery.
â„98%
Purity
Lyophilised
Format
2â3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock â weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator â syringe units in seconds.
Research Use Only â Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
KPV
Lys-Pro-Val
KPV is a synthetic tripeptide (Lys-Pro-Val) comprising the C-terminal amino acids 11-13 of alpha-melanocyte-stimulating hormone (α-MSH). It represents the smallest biologically active fragment of α-MSH that retains anti-inflammatory activity, making it of interest as a more stable and lower-molecular-weight alternative to full-length α-MSH for inflammatory conditions.
KPV interacts with melanocortin receptors â particularly MC1R and MC3R on immune cells and intestinal epithelium â downregulating NF-ÎșB activation and reducing transcription of pro-inflammatory mediators including TNF-α, IL-1ÎČ, IL-6, and IL-8. Notably, KPV also appears to act intracellularly and at the nucleus independently of surface receptor engagement. In intestinal epithelial models, KPV crosses the apical membrane to act directly within colonocytes â a mechanism distinct from typical receptor pharmacology.
Preclinical research has focused on KPV in models of inflammatory bowel disease (experimental colitis), skin inflammation (contact dermatitis), and wound healing. Topical KPV has demonstrated efficacy in reducing skin inflammation in mouse models. Its small size facilitates mucosal absorption, making oral and topical routes viable for gut and skin applications respectively. Anti-microbial properties have also been described in some pathogen challenge models.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
